[Ketamine for treatment of acute depression]

Ugeskr Laeger. 2013 Sep 9;175(37):2090-3.
[Article in Danish]

Abstract

In clinical trials a single dose of the N-methyl-D-aspartate (NMDA) receptor antagonist ketamine has shown a rapid antidepressant effect in patients with treatment-resistant depression and bipolar depression. The implications of glutaminergic mechanisms in depression and the rapid effect of a single dose of ketamine could open new pathways to understand the pathophysiology of depression and the development of novel rapid-acting antidepressant drugs.

Publication types

  • English Abstract
  • Review

MeSH terms

  • Acute Disease
  • Analgesics, Short-Acting / administration & dosage
  • Analgesics, Short-Acting / adverse effects
  • Analgesics, Short-Acting / chemistry
  • Analgesics, Short-Acting / therapeutic use
  • Anesthetics, Dissociative / administration & dosage
  • Anesthetics, Dissociative / adverse effects
  • Anesthetics, Dissociative / chemistry
  • Anesthetics, Dissociative / therapeutic use
  • Antidepressive Agents / administration & dosage
  • Antidepressive Agents / adverse effects
  • Antidepressive Agents / chemistry
  • Antidepressive Agents / therapeutic use*
  • Bipolar Disorder / drug therapy
  • Depressive Disorder / drug therapy*
  • Excitatory Amino Acid Antagonists / administration & dosage
  • Excitatory Amino Acid Antagonists / adverse effects
  • Excitatory Amino Acid Antagonists / chemistry
  • Excitatory Amino Acid Antagonists / therapeutic use*
  • Humans
  • Ketamine / administration & dosage
  • Ketamine / adverse effects
  • Ketamine / chemistry
  • Ketamine / therapeutic use*
  • Placebos
  • Psychiatric Status Rating Scales
  • Randomized Controlled Trials as Topic
  • Receptors, N-Methyl-D-Aspartate / antagonists & inhibitors
  • Treatment Outcome

Substances

  • Analgesics, Short-Acting
  • Anesthetics, Dissociative
  • Antidepressive Agents
  • Excitatory Amino Acid Antagonists
  • Placebos
  • Receptors, N-Methyl-D-Aspartate
  • Ketamine